Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
Status:
Not yet recruiting
Trial end date:
2026-08-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of Nintedanib with EGFR-TKI
in participants with advanced EGFR-TKI-resistant non-small cell lung cancer